GGGisela Garcia-Arellano

Gisela Garcia-Arellano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gisela Garcia-Arellano has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Body image and sexual function in women with systemic lupus erythematosus: a cross-sectional study

    by Hector Alejandro Martinez-Espinosa, Luciana Yulliet Gaytan-Garcia, Juan Pablo Gonzalez-Morales, Arantza Michelle Nuñez-Elizondo, Regina Esdeyne Rivera-Villafuerte, Juan Angel Iii Garcia-Vargas, Maria Eugenia Corral-Trujillo, Gisela Garcia-Arellano, Ana Cecilia Bardan-Inchaustegui, Jesus Alberto Cardenas-De la Garza, et al.

    Systemic lupus erythematosus (SLE) is a unique experience for each patient, affecting physical, psychological, and social aspects. Furthermore, body image can be deteriorated. Although both dissatisfaction with body image and sexual dysfunction have been reported in SLE, their relationship remains unclear and has not been previously studied in a Mexican population. Our study aims to determine if body image is correlated with sexual function in women with SLE. A cross-sectional study was conducted in the rheumatology service including adult women aged 18 years or older who met the 2019 EULAR/ACR classification criteria for SLE. Participants completed the Body Esteem Scale (BES), Female Sexual Function Index (FSFI), Rosenberg Self-Esteem Scale (RSES) and Short Form-36 Health Survey (SF-36). All patients provided informed consent. Data from 68 women were analyzed. The mean age was 37.3 ± 13.4 years. Sexual dysfunction was prevalent in 57.4% (n = 39/68) of the participants. While no significant association was found between global body image (BES) and sexual function (r = 0.14, p = 0.24), the sexual attractiveness subdomain was significantly lower in women with dysfunction (3.22 vs. 3.66, p = 0.0125). In the multivariable logistic regression analysis, the primary independent predictors of sexual dysfunction were partner status (OR 0.12; 95% CI 0.02–0.49, p = 0.001), age (OR 1.09; 95% CI 1.02–1.17, p = 0.012), and self-esteem (OR 0.75; 95% CI 0.58–0.92, p = 0.018). Our findings may serve to improve treatment for patients with sexual dysfunction and SLE by offering therapies aimed at enhancing their self-esteem.

  • Correlations Between Neutrophil/Lymphocyte Ratio, Platelets/Lymphocyte Ratio, and Systemic Immune‐Inflammation Index and Fatigue in Systemic Lupus Erythematosus

    by Maria Fernanda Ortiz‐Nuño, Griselda Serna‐Peña, Gisela Garcia‐Arellano, Jesus Alberto Cardenas‐De la Garza, Juan Pablo Toledo‐Motta, Miguel Angel Villarreal‐Alarcon, Dionicio Angel Galarza‐Delgado

  • Impact of intimate partner violence on quality of life and disease activity in women with systemic lupus erythematosus

    by Emmanuel Campos-Tinajero, Maria Fernanda Ortiz-Nuño, Diana Paola Flores-Gutierrez, Jorge Antonio Esquivel-Valerio, Gisela Garcia-Arellano, Jesus Alberto Cardenas-De la Garza, Estefania Aguilar-Rivera, Dionicio A Galarza-Delgado, Griselda Serna-Peña

    Objective: Stress and trauma are psychosocial factors with an impact on the course of systemic lupus erythematosus (SLE). The influence of violence on SLE has not been entirely explored, even though women (including patients with rheumatic diseases) are a vulnerable population to any form of violence. This study aims to assess the prevalence and impact of intimate partner violence (IPV) on health-related quality of life in women with SLE. Methods: An observational, cross-sectional, and analytical study was conducted at a rheumatology clinic of a university hospital from September 2022 and September 2023. We evaluated the presence of IPV in 85 women with SLE with the Hurt, Insulted, Threatened with Harm and Screamed at (HITS) questionnaire and the Index of Spouse Abuse (ISA), and quality of life with LupusQoL. Results: The prevalence by HITS score of past-year IPV was 24.4% and of lifetime IPV was 36.5%. Past-year non-physical violence was present in 17.1% of patients by ISA, and 27.1% were victims in their lifetime. While in physical violence, 7.3% were victims in the previous year and 21.2% in their lifetime. The total quality of life and the emotional domain by LupusQoL were diminished in victims of past-year IPV, compared to those who weren’t exposed ( p = .018 and p = .036, respectively). Past-year HITS score correlated with the Physician Global Assessment (PGA) (rho = 0.301, p = .006), while lifetime HITS score correlated with PGA (rho = 0.329, p = .002) and SLEDAI-2K (rho = 0.277, p = .010). Conclusion: We found that one in four women suffered IPV in the previous year, and those who were exposed had diminished quality of life. Also, the severity of the abuse correlated with disease activity. Our findings emphasize the importance of comprehensive care for patients with SLE.


  • Clinical Images: Burton line and scar hyperpigmentation in a patient with severe lead poisoning and saturnine gout

    by Gisela Garcia‐Arellano, Maria F. Ortiz‐Nuño, Griselda Serna‐Peña, Juan P. Toledo‐Motta, Ana V. Vasquez‐Gallegos, Dionicio A. Galarza‐Delgado, Jesus A. Cardenas‐De la Garza

  • Anti‐Ku syndrome: A novel cause of fever, arthritis and rash

    by Gisela García‐Arellano, Rosa Icela Arvizu‐Rivera, Rodrigo de Jesus Castillo‐De la Garza, Dionicio Ángel Galarza‐Delgado, Jesus Alberto Cardenas‐De la Garza

  • Quality indicators and satisfaction with care in patients with systemic lupus erythematosus

    by Griselda Serna-Peña, Rodrigo J. Castillo-De la Garza, Gisela Garcia-Arellano, Jesus Alberto Cardenas-De la Garza, Leonardo R. Aguilar-Rivera, Axel A. de Leon-Perez, Estefania Aguilar-Rivera, Camila E. Vazquez-Perez, Dionicio A. Galarza-Delgado, Jorge A. Esquivel-Valerio

    Grading the quality of care in patients with systemic lupus erythematosus and determining its relationship with care satisfaction may recognize gaps that could lead to better clinical practice. Eighteen quality indicators (QIs) were recently developed and validated for patients with SLE based on the 2019 EULAR management recommendations. Few studies have analyzed the relationship between quality of care and care satisfaction in patients with lupus. This was a cross-sectional study. We included patients at least 18 years old who met the EULAR/ACR 2019 classification criteria for SLE. We interviewed patients and retrieved data from medical records to assess their compliance with a set of 18 EULAR-based QIs. We calculated each QI fulfillment as the proportion of fulfilled QI divided by the number of eligible patients for each indicator. Care satisfaction was evaluated with the satisfaction domain of LupusPRO version 1.7. Spearman correlation coefficient was used to determine the relationship between quality of care and care satisfaction. Seventy patients with a median age of 33 (IQR 23–48) were included, 90% were women. Overall adherence was 62.29%. The median care satisfaction was 100. Global adherence to the 18-QIs and the care satisfaction score revealed no correlation (r = 0.064, p = 0.599). Higher QI fulfillment was found in the group with remission versus the moderate-high activity group (p = 0.008). In our study, SLE patients in remission had higher fulfillment of quality indicators. We found no correlation between the quality of care and satisfaction with care.


  • Association of soluble cell adhesion molecules and lipid levels in rheumatoid arthritis patients

    by Iris J. Colunga-Pedraza, Dionicio A. Galarza-Delgado, Natalia Guajardo-Jauregui, Jesus A. Cardenas-De la Garza, Gisela Garcia-Arellano, Rosa I. Arvizu-Rivera, Andrea N. Garza-Cisneros, Alexis Garcia-Heredia, Mario A. Balderas-Palacios, Jose R. Azpiri-Lopez

    Objectives To evaluate the relationship between soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble intracellular adhesion molecule-1 (sICAM-1), and lipid levels in rheumatoid arthritis (RA) patients with and without carotid plaque (CP). Methods Cross-sectional study nested of a RA cohort. RA patients without a previous cardiovascular event or statins’ therapy, aged 40–75 years were recruited at an outpatient cardio-rheumatology clinic. Carotid ultrasound was performed in all study subjects. RA patients with CP were included and matched to RA patients without CP by age, gender, and traditional cardiovascular risk factors. Blood samples were drawn at the time of recruitment to measure sVCAM-1, sICAM-1, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and lipid levels. Correlations between cell adhesion molecules, disease activity indexes, ESR and CRP with lipid levels were assessed with Spearman’s correlation coefficient (rs). Results We included 71 RA patients, 37 with CP and 34 without CP. RA (n = 71) patients had a moderate negative correlation of sVCAM-1 with total cholesterol (TC) (rs = − 0.366, p = 0.002) and low-density lipoprotein (LDL) (rs = − 0.316, p = 0.007), and a small negative correlation with high-density lipoprotein (rs = − 0.250, p = 0.036). ESR showed a small negative correlation with LDL (rs = − 0.247, p = 0.038). Patients with CP had a moderate negative correlation between sVCAM and TC (rs = − 0.405, p = 0.013). Patients without CP showed a moderate negative correlation between sVCAM with TC (rs = − 0.364, p = 0.034) and LDL (rs = − 0.352, p = 0.041), and sICAM with VLDL (rs = − 0.343, p = 0.047). Conclusions RA patients showed an inverse association of sVCAM-1 and lipid levels. More studies are needed to define the precise role of sVCAM-1 in the lipid paradox of RA. Key Points • In RA patients with and without atherosclerosis, higher sVCAM-1 titers were associated with lower TC, LDL and HDL, and higher levels of ESR associated with lower LDL. • Higher levels of sVCAM-1 were associated with lower TC in RA patients with atherosclerosis, and with lower TC and LDL in RA patients without atherosclerosis. • There was an inverse association of sICAM-1 with VLDL, in RA patients without atherosclerosis. • sVCAM-1 may have a role in the detection of paradoxical lipid levels in RA, but more research is needed to validate our findings.


  • Cardiovascular risk reclassification according to six cardiovascular risk algorithms and carotid ultrasound in psoriatic arthritis patients

    by Dionicio A. Galarza-Delgado, Jose R. Azpiri-Lopez, Iris J. Colunga-Pedraza, Natalia Guajardo-Jauregui, Alejandra B. Rodriguez-Romero, Salvador Lugo-Perez, Jesus A. Cardenas-De la Garza, Rosa I. Arvizu-Rivera, Diana E. Flores-Alvarado, Octavio Ilizaliturri-Guerra, et al.

    The objective was to compare the prevalence of subclinical atherosclerosis and cardiovascular risk (CVR) reclassification using six CVR algorithms and a carotid ultrasound in psoriatic arthritis (PsA) patients and controls. The method was cross-sectional study. A total of 81 patients aged 40–75 years, who fulfilled the 2006 CASPAR criteria and 81 controls matched by age, gender, and comorbidities were recruited. CVR was evaluated according to six CVR algorithms, including Framingham Risk Score (FRS)-lipids, FRS-body mass index (BMI), Atherosclerotic Cardiovascular Disease (ASCVD) Algorithm, Systematic Coronary Risk Evaluation (SCORE), QRISK3, and Reynolds Risk Score (RRS). A carotid ultrasound was performed to identify the presence of carotid plaque (CP) defined as a carotid intima media thickness ≥ 1.2 mm or a focal narrowing of the surrounding lumen ≥ 0.5mm. Patients with presence of CP, classified in the low-moderate risk by the CVR algorithms, were reclassified to a higher risk category. CP was more prevalent in PsA patients (44.4% vs 24.7%, p = 0.008), as was subclinical atherosclerosis (51.9% vs 33.3%, p = 0.017). When comparing the CVR reclassification to a higher risk category, a difference was found in the six CVR algorithms. The reclassification was more prevalent in PsA patients: 30.8% vs 12.3%, p = 0.004 with FRS-lipids; 28.4% vs 9.9%, p = 0.003 with FRS-BMI; 40.7% vs 19.8%, p = 0.003 with SCORE; 30.9% vs 16.0%, p = 0.026 with ASCVD algorithm; 37.0% vs 19.8%, p = 0.015 with RRS; and 33.3% vs 16.0%, p = 0.011 with QRISK3. The CVR algorithms underestimate the actual CVR of PsA patients. A carotid ultrasound should be considered as part of the CVR evaluation of PsA patients. Key points • Subclinical atherosclerosis was more prevalent in psoriatic arthritis patients than controls. • Cardiovascular risk reclassification, through a carotid ultrasound, according to traditional cardiovascular risk algorithms was more common in psoriatic arthritis patients. • The cardiovascular risk algorithm that showed the lowest reclassification rate in psoriatic arthritis patients was the FRS-BMI. • All cardiovascular risk algorithms underestimate the actual risk of psoriatic arthritis patients, preventing the initiation of an adequate cardiovascular treatment.


  • Open Access

    Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study

    by Jorge Antonio Esquivel-Valerio, Cassandra Michele Skinner-Taylor, Ilse Andrea Moreno-Arquieta, Jesus Alberto Cardenas-De la Garza, Gisela Garcia-Arellano, Patricia Ludivina Gonzalez-Garcia, Fatima del Rocio Almaraz-Juarez, Dioncio Angel Galarza-Delgado

    Data regarding COVID-19 vaccine efficacy and adverse events (AE) in patients with autoimmune and inflammatory rheumatic diseases (AIIRD) have been published recently although these mostly include the mRNA vaccines (Pfizer-BioNTech and Moderna) and the ChAdOx1 nCoV-19/AZD1222 (Oxford-AstraZeneca). This research aimed to study the prevalence of AE presented with six different SARS-CoV-2 vaccines {ChadOX1 nCoV-19 (AZD1222), Ad5-nCoV2, Ad26.COV2.S, mRNA-1273, BNT162b2, and CoronaVac} in Mexican patients with AIIRD. We performed a cross-sectional study about vaccine history. Two hundred and twenty five consecutive patients were recruited, mean age was 50.7 years and the majority (n = 213; 94.6%) were females. One hundred and seven (47.5%) received BNT162b2 mRNA, 34 (15.1%) Ad5-nCoV, 29 (12.8%) mRNA-1273, 28 (12.4%) ChAdOX1 nCoV-19 (AZD1222), 22 (9.7%) CoronaVac and 5 (2.2%) Ad26.COV2.S. The vaccines that had the most AE proportionally to the number of patients vaccinated were Janssen (5; 100%) followed by Pfizer-BioNTEch (86; 80%) and CanSinoBIO (27; 79.4%). Localized pain was the most frequent (158; 70.2%) AE. Fatigue (78; 34.7%), headache (69; 30.6%) and muscle ache (66; 29.3%) were the most common systemic symptoms. No serious AE that required medical attention or hospitalization were reported. The current results support the safety of different COVID-19 vaccines in patients with AIIRD. This information can help fight vaccine hesitancy in this population.


  • Carotid Plaque Is Not Associated With Increased Levels of Interleukin 1, Interleukin 6, and Tumor Necrosis Factor α in Rheumatoid Arthritis

    by Rosa I. Arvizu-Rivera, Jose R. Azpiri-Lopez, Iris J. Msc Colunga-Pedraza, Jesus A. Cardenas-De la Garza, Raymundo Vera-Pineda, Gisela Garcia-Arellano, Adrian Martinez-Moreno, Estefania E. Abundis-Marquez, Dionicio A. Galarza-Delgado

    An abstract is unavailable. This article is available as a PDF only.